You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest regulatory news and FDA approvals.
The CHMP opinion is based on data from a Phase I/II study of dostarlimab in mismatch repair-deficient or microsatellite instability-high endometrial cancer.
News items for the week of Feb. 22, 2021.
Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.
The UK's Medicines and Healthcare products Regulatory Agency approved the agent together with trastuzumab and chemo based on the Phase II HER2CLIMB trial.
News items for the week of Feb. 15, 2021.